Study of 2-HOBA Treatment to Reduce Blood Pressure and Immune Activation in Women with Stable Systemic Lupus Erythematosus

What this Trial Is About

Researchers are evaluating the effects of scavenging isolevuglandins IsoLGs with 2-HOBA on blood pressure and immune activation in patients with systemic lupus erythematosus SLE, an autoimmune disease linked to high rates of hypertension and cardiovascular risks. This phase II randomized, placebo-controlled, double-blind, cross-over trial aims to understand the role of IsoLGs in SLE-related hypertension and immune responses. Participants will receive either placebo or 500mg of 2-HOBA acetate three times a day for 8 weeks, followed by a 4-week washout period, then switch to the other treatment for another 8 weeks. The study includes two treatment sequences placebo first then 2-HOBA, or 2-HOBA first then placebo. This design allows comparison of blood pressure and immune activity changes between treatments. During the study, 42 women with stable SLE will undergo evaluations including 24-hour blood pressure monitoring and measurement of NETosis at baseline and at weeks 8, 12, and 20. Researchers will monitor immune activation and blood pressure changes to assess the impact of 2-HOBA compared to placebo. The total participation includes treatment periods and washout spanning 20 weeks.

2-HOBA in Systemic Lupus Erythematosus